Last10K.com

Abvc Biopharma, Inc. (ABVC) SEC Filing 8-K Material Event for the period ending Wednesday, August 2, 2023

American Brivision

HISTORY TOOLS
CIK: 1173313 Ticker: ABVC

View differences made from one to another to evaluate American Brivision's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Brivision.

Continue

Assess how American Brivision's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

American Brivision's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

American Brivision provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Term Sheet Dated July 31, 2023
Exhibit 99.1: Press Release Dated August 1, 2023
Ticker: ABVC
CIK: 1173313
Form Type: 8-K Corporate News
Accession Number: 0001213900-23-062628
Submitted to the SEC: Wed Aug 02 2023 5:00:18 PM EST
Accepted by the SEC: Wed Aug 02 2023
Period: Wednesday, August 2, 2023
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/abvc/0001213900-23-062628.htm